Acanthosis nigricans - Awọn Nigricans Acanthosis
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
O wọpọ ni awọn eniyan ti o sanra.
References
Acanthosis nigricans jẹ ifihan awọ-ara ti ipo abẹlẹ. Nigbagbogbo o farahan ni awọn agbo awọ bi ọrun, awọn apa, ati ikun, ti o dabi awọn abulẹ dudu velvety pẹlu awọn egbegbe ti ko mọ. Ipo yii nigbagbogbo ni asopọ si àtọgbẹ ati itọju insulini, ṣugbọn ni awọn iṣẹlẹ to ṣọwọn, o le tọka si akàn inu ara. O tun le ṣafihan nitori awọn ọran homonu tabi lati mu awọn oogun kan pato gẹgẹbi awọn sitẹriọdu ati awọn oogun iṣakoso ibi.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) jẹ ipo awọ ara ti o wọpọ ti o sopọ si ọpọlọpọ awọn ọran ilera bii resistance insulin, àtọgbẹ, isanraju, awọn aarun kan, awọn iṣoro homonu, ati awọn aati si awọn oogun. Itọju AN fojusi lori koju awọn iṣoro ilera ti o wa labẹ. Ni ibẹrẹ, awọn dokita ṣayẹwo fun awọn ami ti iṣọn-aisan insulin resistance, eyiti o pẹlu isanraju, idaabobo awọ giga, titẹ ẹjẹ giga, ati iru àtọgbẹ 2. Awọn dokita nigbagbogbo ṣe ilana topical retinoids bi yiyan itọju akọkọ, eyiti o le ṣe iranlọwọ pẹlu didan awọ ara. Sibẹsibẹ, wọn le ma koju ni kikun awọ okunkun. Awọn aṣayan itọju miiran (salicylic acid, podophyllin, urea, calcipotriol) tun nilo ohun elo loorekoore.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Awọn idi
O maa nwaye ni awọn ẹni-kọọkan ti o kere ju ọdun 40 lọ, o le jẹ jogun jiini ati pe o ni nkan ṣe pẹlu isanraju tabi awọn endocrinosis, gẹgẹbi hypothyroidism, acromegaly, arun ọjẹ polycystic, diabetes-sooro insulin tabi arun Cushing.
○ Itọju - Oògùn OTC
#40% urea cream